Viridian’s Accelerating Pipeline and $875M Cash Position Set Up for Key 2026 Milestones
Market Chameleon (Thu, 26-Feb 2:39 AM ET)
Business Wire (Thu, 26-Feb 7:01 AM ET)
Viridian Grants 16,650 Inducement Options as Pipeline Progresses in Thyroid Eye Disease
Market Chameleon (Fri, 9-Jan 4:40 AM ET)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Thu, 8-Jan 4:01 PM ET)
Viridian Therapeutics Prepares for Transformational 2026
Business Wire (Tue, 6-Jan 7:01 AM ET)
Market Chameleon (Mon, 22-Dec 6:17 AM ET)
Business Wire (Mon, 22-Dec 7:00 AM ET)
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Viridian Therapeutics trades on the NASDAQ stock market under the symbol VRDN.
As of March 19, 2026, VRDN stock price climbed to $27.83 with 433,233 million shares trading.
VRDN has a beta of 0.84, meaning it tends to be less sensitive to market movements. VRDN has a correlation of 0.09 to the broad based SPY ETF.
VRDN has a market cap of $2.65 billion. This is considered a Mid Cap stock.
Last quarter Viridian Therapeutics reported $132,000 in Revenue and -$1.08 earnings per share. This fell short of revenue expectation by $-17 million and missed earnings estimates by -$.12.
In the last 3 years, VRDN traded as high as $34.29 and as low as $9.90.
The top ETF exchange traded funds that VRDN belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
VRDN has outperformed the market in the last year with a return of +83.8%, while the SPY ETF gained +19.0%. However, in the most recent history, VRDN shares have underperformed the stock market with its stock returning -11.9% in the last 3 month period and -8.4% for the last 2 week period, while SPY has returned -1.8% and -3.6%, respectively.
VRDN support price is $26.78 and resistance is $28.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRDN shares will trade within this expected range on the day.
